Jubilant Pharmova profit halves to ₹3,975 m on Montreal remediation costs
Revenue grew 14.5% to ₹82,796 million, but net profit fell 52% as the company absorbed ₹535 million in costs to fix its Montreal facility.
— 9 earlier stories on Jubilant Pharmova Ltd. →What's new
- Annual net profit fell 52% to ₹3,975 million, weighed down by ₹535 million in Montreal remediation costs.
- Revenue grew 14.5% to ₹82,796 million, but profit was eroded by exceptional items.
- Board held dividend at ₹5 per share; audit opinion unmodified.
Why this matters
The top-line growth is solid, but the profit story is now dictated by the cost of fixing a compliance failure at one site. The ₹535 million remediation charge for Montreal, which is under the most severe regulatory penalty (OAI status), is the primary drag. Until that is resolved, earnings power remains constrained.
What we're watching
- Timeline and total cost for resolving the Montreal facility's OAI status.
- Whether the ₹535 million charge is a one-off or the start of a multi-year remediation spend.
- Impact of the new Labour Code on future gratuity and compensation costs.
The full read
Jubilant Pharmova's FY25-26 results show a stark divergence. Consolidated revenue rose 14.5% to ₹82,796 million, a healthy topline. Net profit, however, plunged 52% to ₹3,975 million from ₹8,363 million a year earlier. The culprit is ₹535 million in remediation costs at its Montreal facility, which is under OAI regulatory status, plus a ₹100 million hit from new Labour Codes. The company held its dividend at ₹5 per share and the audit is clean, but the earnings trajectory is now being shaped by the cost of resolving a compliance failure at a single site. The revenue growth is real. The profit story, until Montreal is sorted, is not.
Questions answered
- Why did profit fall despite solid revenue growth?
- Revenue grew 14.5% to ₹82,796 million, but net profit fell 52% to ₹3,975 million due to ₹535 million in remediation costs for the Montreal facility and a ₹100 million charge from new Labour Codes. The operational performance was overshadowed by these exceptional items.
- What is the significance of the Montreal OAI status?
- OAI (Official Action Indicated) is the most serious regulatory classification a facility can receive, signaling significant compliance failures. The ₹535 million in costs are to remediate those issues, and the facility will remain a profitability drag until the status is lifted.
- How did the company treat its dividend?
- The board recommended a final dividend of ₹5 per share, unchanged from the prior year. This was maintained despite the 52% drop in net profit, indicating a priority on consistent payouts.
- Is the profit decline structural or temporary?
- The ₹535 million remediation charge is the primary driver and could be a multi-year cost until Montreal is fixed. The ₹100 million Labour Code impact, however, represents a structural increase in the cost base.
Jubilant Pharmova Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLPHARMA →- 22 May 2026 · 2:32 PM IST Jubilant Pharmova profit halves to ₹3,975 m on Montreal remediation costs
- 6d ago Jubilant Pharmova's ₹53.37 cr tax setback
- 12d ago Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
- 17d ago Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
- 38d ago USFDA hits Jubilant's Montreal plant with a Warning Letter